FoghornTherapeutics Inc. FHTX, a clinical-stage company, announced that its pre-clinical candidate, FHD-909, has been selected by Eli Lilly ... 2021 agreement, Foghorn and Lilly are co-developing ...

Shares of Foghorn Therapeutics Inc. fell more than ... resources to its proprietary pipeline and collaborations with Eli Lilly, including the clinical-stage SMARCA2 inhibitor FHD-909.

Foghorn Therapeutics on Monday said it is ending ... its other pipeline candidates and its collaboration programs with Eli Lilly. The company said its $267.4 million in cash, equivalents and ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX ... set by standard-of-care venetoclax and believes Eli Lilly (LLY) allied SMARCA2 inhibitor FHD-909 “remains the ...

Foghorn Therapeutics (FHTX ... The Company will prioritize its proprietary pipeline and Lilly (LLY) collaboration programs, including the clinical-stage selective SMARCA2 inhibitor FHD-909.

The partnership with Eli Lilly represents a significant opportunity for Foghorn Therapeutics. The $300 million upfront payment provides substantial financial resources to advance the company's ...

(Reuters) -Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are suffering this morning.